In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biopharma Dealmaking Quarterly Statistics, Q1 2014

A look at financing, M&A, and alliance activity January–March 2014

Executive Summary

Biopharma financing totaled $9.8 billion, a 53% increase over Q4 2013. Twenty-two M&As were completed with a combined potential value reaching $31.3 billion, and there were 103 biopharma alliances totaling $1.9 billion in potential pre-commercialization value, down 30% from the previous quarter.


Related Content

Deal Watch: Genentech Pays Big For Seragon’s Early Assets
Actavis’ Big Bet On A Diversified Hybrid Model
Bristol Gets Five Primed For Immuno-Oncology Expansion
ASCEND Data Puts InterMune’s Pirfenidone On Top
Onkaido Therapeutics Inc.
Strategic Spin-Outs: Biotechs Structure Their Progeny For Success
Does Alnylam Lift All Oligo Boats? The Dicerna IPO
How And Why Genzyme And Alnylam Expanded Their Alliance


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts